Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system disease diagnosis and treatment technologies, has announced its participation in the Virtual Investor Closing Bell Series scheduled for Wednesday, January 22, 2025, at 4:00 PM ET.
During the event, CEO Brad Hauser will deliver a corporate overview and business outlook. The format includes a moderated discussion with a live Q&A session where investors can submit questions. The company will address as many queries as time permits.
The presentation will be accessible through a live video webcast on the Events page in the Investors section of autonomix.com. A replay will be available two hours after the live event and remain accessible for 90 days.
Autonomix Medical (NASDAQ: AMIX), un'azienda di dispositivi medici specializzata nelle tecnologie per la diagnosi e il trattamento delle malattie del sistema nervoso, ha annunciato la sua partecipazione alla Virtual Investor Closing Bell Series prevista per mercoledì 22 gennaio 2025, alle 16:00 ET.
Durante l'evento, il CEO Brad Hauser presenterà una panoramica aziendale e una prospettiva commerciale. Il formato prevede una discussione moderata con una sessione di domande e risposte dal vivo in cui gli investitori possono inviare domande. L'azienda affronterà quante più interrogativi possibile nei limiti del tempo disponibile.
La presentazione sarà accessibile tramite un webcast video in diretta sulla pagina Eventi nella sezione Investitori di autonomix.com. Una registrazione sarà disponibile due ore dopo l'evento dal vivo e rimarrà accessibile per 90 giorni.
Autonomix Medical (NASDAQ: AMIX), una empresa de dispositivos médicos especializada en tecnologías para el diagnóstico y tratamiento de enfermedades del sistema nervioso, ha anunciado su participación en la Virtual Investor Closing Bell Series programada para miércoles 22 de enero de 2025, a las 4:00 PM ET.
Durante el evento, el CEO Brad Hauser ofrecerá una visión general de la empresa y las perspectivas comerciales. El formato incluye una discusión moderada con una sesión de preguntas y respuestas en vivo donde los inversores pueden enviar sus preguntas. La empresa abordará el mayor número de consultas posible dentro del tiempo disponible.
La presentación será accesible a través de una transmisión en vivo en video en la página de Eventos en la sección de Inversores de autonomix.com. Una repetición estará disponible dos horas después del evento en vivo y permanecerá accesible durante 90 días.
Autonomix Medical (NASDAQ: AMIX), 신경계 질병의 진단 및 치료 기술을 전문으로 하는 의료 기기 회사가 가상 투자 종가 종 소리 시리즈에 참여한다고 발표했습니다. 이 행사는 2025년 1월 22일 수요일, 동부 표준시 오후 4:00에 예정되어 있습니다.
이벤트 중에 CEO 브래드 하우저가 기업 개요와 비즈니스 전망을 발표합니다. 형식에는 투자자가 질문을 제출할 수 있는 실시간 Q&A 세션이 포함된 주최 토론이 있습니다. 회사는 가능할 때까지 많은 질문을 다룰 것입니다.
프레젠테이션은 autonomix.com의 투자자 섹션 이벤트 페이지에서 실시간 비디오 웹캐스트를 통해 접근이 가능합니다. 라이브 이벤트 후 2시간 이내에 다시 보기 선택이 가능하며, 90일 동안 지속적으로 접근할 수 있습니다.
Autonomix Medical (NASDAQ: AMIX), une entreprise de dispositifs médicaux spécialisée dans les technologies de diagnostic et de traitement des maladies du système nerveux, a annoncé sa participation à la Virtual Investor Closing Bell Series prévue pour mercredi 22 janvier 2025, à 16h00 ET.
Lors de cet événement, le PDG Brad Hauser présentera un aperçu de l'entreprise et des perspectives d'affaires. Le format inclut une discussion modérée avec une session de questions-réponses en direct où les investisseurs peuvent soumettre des questions. L'entreprise répondra à un maximum de requêtes dans le temps imparti.
La présentation sera accessible via un webcast vidéo en direct sur la page Événements dans la section Investisseurs de autonomix.com. Un rediffusion sera disponible deux heures après l'événement en direct et restera accessible pendant 90 jours.
Autonomix Medical (NASDAQ: AMIX), ein Medizintechnikunternehmen, das sich auf Diagnose- und Behandlungstechnologien für Erkrankungen des Nervensystems spezialisiert hat, hat seine Teilnahme an der Virtual Investor Closing Bell Series angekündigt, die für Mittwoch, den 22. Januar 2025, um 16:00 Uhr ET geplant ist.
Im Rahmen der Veranstaltung wird CEO Brad Hauser einen Überblick über das Unternehmen und die Geschäftsaussichten geben. Das Format umfasst eine moderierte Diskussion mit einer live Q&A-Session, in der Investoren Fragen einreichen können. Das Unternehmen wird so viele Anfragen wie möglich innerhalb der zur Verfügung stehenden Zeit beantworten.
Die Präsentation wird über einen Live-Video-Webcast auf der Veranstaltungsseite im Investorenbereich von autonomix.com zugänglich sein. Eine Wiederholung wird zwei Stunden nach der Live-Veranstaltung verfügbar sein und 90 Tage lang zugänglich bleiben.
- None.
- None.
Live video webcast on Wednesday, January 22nd at 4:00 PM ET
THE WOODLANDS, TX, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, January 22, 2025 at 4:00 PM ET.
As part of the event, Brad Hauser, Chief Executive Officer of Autonomix, will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
A live video webcast will be available on the Events page under the Investors section of the Company’s website (autonomix.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
When is Autonomix Medical (AMIX) participating in the Virtual Investor Closing Bell Series?
How can investors watch the AMIX Virtual Investor Closing Bell presentation?
How long will the AMIX Virtual Investor Closing Bell replay be available?
Will there be a Q&A session during the AMIX Virtual Investor presentation?
What topics will be covered in the AMIX Virtual Investor presentation?
